Quantifying the Treatment Effect of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy-Reply

Rahman Shah^{1

2}, Sunil V Rao³, David E Kandzari⁴

Affiliations

¹ Veterans Affairs Medical Center, Memphis, Tennessee.
² Section of Cardiovascular Medicine, School of Medicine, University of Tennessee, Memphis.
³ Duke Clinical Research Institute, Durham, North Carolina.
⁴ Piedmont Heart Institute, Atlanta, Georgia.

Comment

Rahman Shah et al. JAMA Cardiol. 2019.

. 2019 May 1;4(5):494-495.

doi: 10.1001/jamacardio.2019.0556.

Rahman Shah^{1

2}, Sunil V Rao³, David E Kandzari⁴

¹ Veterans Affairs Medical Center, Memphis, Tennessee.
² Section of Cardiovascular Medicine, School of Medicine, University of Tennessee, Memphis.
³ Duke Clinical Research Institute, Durham, North Carolina.
⁴ Piedmont Heart Institute, Atlanta, Georgia.

No abstract available

Comment on

Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy: A Meta-analysis.
Shah R, Rao SV, Latham SB, Kandzari DE. Shah R, et al. JAMA Cardiol. 2018 Nov 1;3(11):1050-1059. doi: 10.1001/jamacardio.2018.3551. JAMA Cardiol. 2018. PMID: 30383145 Free PMC article.
Quantifying the Treatment Effect of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy.
Zemplenyi M, Wei LJ. Zemplenyi M, et al. JAMA Cardiol. 2019 May 1;4(5):494. doi: 10.1001/jamacardio.2019.0546. JAMA Cardiol. 2019. PMID: 30916712 No abstract available.